FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment. Patients who receive surgery alone may experience long-term side effects including infertility. The purpose of this research study is to determine whether giving neo-adjuvant chemotherapy prior to surgery can maintain fertility in patients with invasive cervical cancer. The neo-adjuvant chemotherapy will consist of a platinum-based chemotherapy drug cisplatin or carboplatin, with a chemotherapy drug called paclitaxel. These are common chemotherap

Trial Details

NCT ID
NCT04016389
Phase
NA
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • Cisplatin
  • Carboplatin
  • Paclitaxel
  • Trachelectomy
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327
  • Toronto, Ontario, Canada|43.65333,-79.38389
  • Toronto, Ontario, Canada|43.65333,-79.38389
  • Québec, Quebec, Canada|46.81228,-71.21454

Key Eligibility Criteria

  • Part 1 - Eligibility Criteria for Neoadjuvant Chemotherapy
  • Patients must have histologically confirmed invasive cervical cancer with adenocarcinoma, adenosquamous or squamous histology and FIGO 2018 IB2 mea…
  • Patients must be premenopausal and wish to preserve fertility.
  • At time of registration, patient may not have had any prior therapy to treat their cancer lesion.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →